Meridian Bioscience Stock Price, News & Analysis (NASDAQ:VIVO)

$13.55 -0.65 (-4.58 %)
(As of 12/15/2017 04:57 AM ET)
Previous Close$14.20
Today's Range$13.55 - $14.30
52-Week Range$10.75 - $18.35
Volume472,400 shs
Average Volume319,278 shs
Market Capitalization$595.25 million
P/E Ratio20.74
Dividend Yield3.55%
Beta0.89

About Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience logoMeridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

Receive VIVO News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:VIVO
CUSIP58958410
Phone513-271-3700

Debt

Debt-to-Equity Ratio0.30%
Current Ratio5.85%
Quick Ratio4.04%

Price-To-Earnings

Trailing P/E Ratio20.74
Forward P/E Ratio20.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$200.77 million
Price / Sales2.85
Cash Flow$1.01 per share
Price / Cash13.40
Book Value$4.02 per share
Price / Book3.37

Profitability

Trailing EPS$0.51
Net Income$21.55 million
Net Margins10.74%
Return on Equity17.03%
Return on Assets11.51%

Miscellaneous

Employees640
Outstanding Shares42,220,000

Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?

Meridian Bioscience announced a quarterly dividend on Wednesday, November 8th. Investors of record on Monday, November 20th will be given a dividend of $0.125 per share on Thursday, November 30th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.69%. The ex-dividend date of this dividend is Friday, November 17th. View Meridian Bioscience's Dividend History.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience Inc. (NASDAQ:VIVO) released its quarterly earnings results on Thursday, November, 9th. The company reported $0.15 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.15. The company had revenue of $49.70 million for the quarter, compared to analyst estimates of $48.28 million. Meridian Bioscience had a return on equity of 17.03% and a net margin of 10.74%. The business's revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.14 earnings per share. View Meridian Bioscience's Earnings History.

When will Meridian Bioscience make its next earnings announcement?

Meridian Bioscience is scheduled to release their next quarterly earnings announcement on Wednesday, January, 24th 2018. View Earnings Estimates for Meridian Bioscience.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience updated its FY18 earnings guidance on Thursday, November, 9th. The company provided earnings per share guidance of $0.65-0.68 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.67. The company issued revenue guidance of $207-212 million, compared to the consensus revenue estimate of $205.88 million.

Where is Meridian Bioscience's stock going? Where will Meridian Bioscience's stock price be in 2017?

4 brokers have issued 1 year price targets for Meridian Bioscience's stock. Their forecasts range from $9.00 to $14.00. On average, they anticipate Meridian Bioscience's share price to reach $11.50 in the next year. View Analyst Ratings for Meridian Bioscience.

Who are some of Meridian Bioscience's key competitors?

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the folowing people:

  • John A. Kraeutler, Executive Chairman of the Board, President (Age 68)
  • Lawrence J. Baldini, Executive Vice President and President, Global Operations (Age 56)
  • Richard L. Eberly, Executive Vice President, President, Chief Commercial Officer (Age 54)
  • John P. Kenny, Chief Executive Officer, Director (Age 49)
  • Melissa A. Lueke, Chief Financial Officer, Executive Vice President, Secretary (Age 52)
  • Marco G. Calzavara, President and Managing Director of Meridian Bioscience Europe (Age 61)
  • Vecheslav A. Elagin Ph.D., Executive Vice President - Research and Development (Age 48)
  • Susan D. Rolih, Executive Vice President - Regulatory & Quality Systems (Age 66)
  • David C. Phillips, Lead Independent Director (Age 78)
  • James M. Anderson, Independent Director (Age 74)

Who owns Meridian Bioscience stock?

Meridian Bioscience's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.14%), Bank of New York Mellon Corp (2.07%), Wells Fargo & Company MN (1.51%), Schwab Charles Investment Management Inc. (0.99%), SG Capital Management LLC (0.87%) and Prudential Financial Inc. (0.79%). Company insiders that own Meridian Bioscience stock include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mcilwraith, Lawrence Baldini, Melissa Lueke, Richard Eberly and Vecheslav A Elagin. View Institutional Ownership Trends for Meridian Bioscience.

Who sold Meridian Bioscience stock? Who is selling Meridian Bioscience stock?

Meridian Bioscience's stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Rhumbline Advisers, Wells Fargo & Company MN, Cardinal Capital Management, Systematic Financial Management LP, Virginia Retirement Systems ET AL, California State Teachers Retirement System and Royce & Associates LP. View Insider Buying and Selling for Meridian Bioscience.

Who bought Meridian Bioscience stock? Who is buying Meridian Bioscience stock?

Meridian Bioscience's stock was acquired by a variety of institutional investors in the last quarter, including SG Capital Management LLC, Dimensional Fund Advisors LP, Prudential Financial Inc., Citadel Advisors LLC, First Trust Advisors LP, Los Angeles Capital Management & Equity Research Inc., Dynamic Technology Lab Private Ltd and OxFORD Asset Management LLP. Company insiders that have bought Meridian Bioscience stock in the last two years include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.

How do I buy Meridian Bioscience stock?

Shares of Meridian Bioscience can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Meridian Bioscience's stock price today?

One share of Meridian Bioscience stock can currently be purchased for approximately $13.55.

How big of a company is Meridian Bioscience?

Meridian Bioscience has a market capitalization of $595.25 million and generates $200.77 million in revenue each year. The company earns $21.55 million in net income (profit) each year or $0.51 on an earnings per share basis. Meridian Bioscience employs 640 workers across the globe.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.


MarketBeat Community Rating for Meridian Bioscience (VIVO)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  342
MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Meridian Bioscience (NASDAQ:VIVO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.801.801.831.86
Ratings Breakdown: 1 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.00$14.00$17.00$17.00
Price Target Upside: 6.35% downside6.35% downside12.21% upside12.21% upside

Meridian Bioscience (NASDAQ:VIVO) Consensus Price Target History

Price Target History for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ:VIVO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017Canaccord GenuityReiterated RatingHold$14.00N/AView Rating Details
3/28/2017CL KingInitiated CoverageNeutral -> NeutralHighView Rating Details
1/31/2017Craig HallumDowngradeBuy -> HoldN/AView Rating Details
1/25/2017Piper Jaffray CompaniesSet Price TargetSell$9.00N/AView Rating Details
7/29/2016Hilliard LyonsDowngradeBuy -> HoldN/AView Rating Details
3/29/2016Robert W. BairdReiterated RatingHold$20.00N/AView Rating Details
1/27/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Meridian Bioscience (NASDAQ:VIVO) Earnings History and Estimates Chart

Earnings by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ VIVO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/24/2018        
11/9/2017Q4 2017$0.15$0.15$48.28 million$49.70 millionViewN/AView Earnings Details
7/27/2017Q3 2017$0.16$0.16$49.13 million$50.14 millionViewN/AView Earnings Details
4/28/2017Q2 2017$0.19$0.22$51.16 million$54.13 millionViewN/AView Earnings Details
1/25/2017Q1 2017$0.20$0.15$51.15 million$46.80 millionViewN/AView Earnings Details
11/10/2016Q4 2016$0.14$0.14$47.17 million$47.00 millionViewN/AView Earnings Details
7/28/2016Q3$0.22$0.21$52.85 million$50.70 millionViewN/AView Earnings Details
4/28/2016Q2$0.24$0.24$52.10 million$51.30 millionViewN/AView Earnings Details
1/27/2016Q1$0.21$0.21$48.60 million$47.20 millionViewN/AView Earnings Details
11/5/2015Q4$0.21$0.20$45.70 million$47.10 millionViewN/AView Earnings Details
7/23/2015Q3$0.22$0.22$48.60 million$48.20 millionViewN/AView Earnings Details
4/23/2015Q115$0.24$0.24$50.50 million$51.55 millionViewN/AView Earnings Details
1/22/2015Q414$0.19$0.19$46.20 million$48.00 millionViewN/AView Earnings Details
11/6/2014Q4$0.22$0.20$48.94 million$46.70 millionViewN/AView Earnings Details
7/24/2014Q3$0.22$0.21$47.96 million$47.20 millionViewN/AView Earnings Details
4/24/2014Q214$0.27$0.24$52.18 million$50.13 millionViewN/AView Earnings Details
1/22/2014Q114$0.18$0.18$47.59 million$44.80 millionViewN/AView Earnings Details
11/7/2013Q313$0.23$0.22$49.24 million$48.96 millionViewN/AView Earnings Details
7/25/2013Q3 2013$0.21$0.24$47.00 million$47.10 millionViewN/AView Earnings Details
4/25/2013Q2 2013$0.24$0.24$49.66 million$47.26 millionViewN/AView Earnings Details
1/23/2013Q1 2013$0.19$0.20$44.34 million$45.40 millionViewN/AView Earnings Details
11/8/2012Q412$0.19$0.21$43.22 million$43.70 millionViewN/AView Earnings Details
7/26/2012$0.22$0.21ViewN/AView Earnings Details
4/26/2012$0.21$0.23ViewN/AView Earnings Details
1/25/2012$0.19$0.17ViewN/AView Earnings Details
11/10/2011$0.19$0.18ViewN/AView Earnings Details
7/21/2011$0.21$0.17ViewN/AView Earnings Details
4/21/2011$0.20$0.20ViewN/AView Earnings Details
1/20/2011$0.19$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Meridian Bioscience (NASDAQ:VIVO) Earnings Estimates

2017 EPS Consensus Estimate: $0.79
2018 EPS Consensus Estimate: $0.72
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.17$0.17$0.17
Q2 20171$0.22$0.22$0.22
Q3 20171$0.22$0.22$0.22
Q4 20172$0.16$0.20$0.18
Q1 20181$0.17$0.17$0.17
Q2 20181$0.22$0.22$0.22
Q3 20181$0.17$0.17$0.17
Q4 20181$0.16$0.16$0.16
(Data provided by Zacks Investment Research)

Dividends

Meridian Bioscience (NASDAQ:VIVO) Dividend Information

Most Recent Dividend:11/30/2017
Annual Dividend:$0.50
Dividend Yield:3.69%
Payout Ratio:98.04% (Trailing 12 Months of Earnings)
75.76% (Based on This Year's Estimates)
71.43% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ:VIVO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/8/2017Quarterly$0.133.44%11/17/201711/20/201711/30/2017
7/27/2017Quarterly$0.133.55%8/3/20178/7/20178/17/2017
4/27/2017quarterly$0.133.33%5/4/20175/8/20175/18/2017
1/25/2017quarterly$0.133.91%2/2/20172/6/20172/16/2017
11/10/2016Quarterly$0.204.6%11/17/201611/21/201612/1/2016
7/28/2016quarterly$0.204.13%8/4/20168/8/20168/18/2016
4/28/2016quarterly$0.204.19%5/5/20165/9/20165/19/2016
1/27/2016quarterly$0.204.29%2/4/20162/8/20162/18/2016
11/5/2015quarterly$0.203.89%11/12/201511/16/201511/27/2015
7/23/2015quarterly$0.204.28%7/30/20158/3/20158/13/2015
4/23/2015quarterly$0.204.18%4/30/20155/4/20155/14/2015
1/22/2015quarterly$0.204.51%1/29/20152/2/20152/13/2015
11/6/2014quarterly$0.204.75%11/13/201411/17/201411/28/2014
7/24/2014quarterly$0.203.99%7/31/20148/4/20148/14/2014
4/24/2014quarterly$0.204.05%5/1/20145/5/20145/15/2014
1/22/2014quarterly$0.203.13%1/30/20142/3/20142/14/2014
11/7/2013quarterly$0.193.04%11/14/201311/18/201311/29/2013
7/25/2013quarterly$0.193.13%8/1/20138/5/20138/15/2013
4/25/2013quarterly$0.193.88%5/1/20135/4/20135/14/2013
12/4/2012quarterly$0.1912/14/201212/24/2012
(Data available from 1/1/2013 forward)

Insider Trades

Meridian Bioscience (NASDAQ VIVO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 87.01%
Insider Trades by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ VIVO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2017John A KraeutlerChairmanBuy7,000$13.67$95,690.00View SEC Filing  
2/2/2017Melissa LuekeCFOBuy4,000$12.59$50,360.00View SEC Filing  
1/26/2017Lawrence BaldiniEVPBuy4,000$12.70$50,800.00View SEC Filing  
12/2/2016Vecheslav A ElaginEVPSell7,883$17.30$136,375.90View SEC Filing  
11/30/2016Dwight E EllingwoodDirectorBuy1,020$17.12$17,462.40View SEC Filing  
11/16/2016Richard EberlyEVPSell4,926$17.00$83,742.00View SEC Filing  
11/4/2016John A KraeutlerChairmanBuy5,000$16.13$80,650.00View SEC Filing  
11/3/2016Lawrence BaldiniEVPBuy4,900$16.00$78,400.00View SEC Filing  
8/11/2016John McilwraithDirectorBuy1,000$19.57$19,570.00View SEC Filing  
4/29/2016Catherine SazdanoffDirectorBuy7,700$19.20$147,840.00View SEC Filing  
12/9/2015Vecheslav A ElaginEVPSell7,500$19.75$148,125.00View SEC Filing  
12/1/2015Richard EberlyEVPSell4,934$19.61$96,755.74View SEC Filing  
3/2/2015Marviette D JohnsonVPSell1,917$19.91$38,167.47View SEC Filing  
1/23/2015Dwight E EllingwoodDirectorBuy1,980$17.74$35,125.20View SEC Filing  
12/1/2014Susan RolihEVPSell11,219$16.46$184,664.74View SEC Filing  
11/21/2014Dwight E EllingwoodDirectorBuy1,000$16.08$16,080.00View SEC Filing  
11/18/2014John A KraeutlerCEOSell10,500$16.20$170,100.00View SEC Filing  
11/18/2014Melissa LuekeCFOSell6,713$16.20$108,750.60View SEC Filing  
11/11/2014David PhillipsDirectorBuy10,000$16.89$168,900.00View SEC Filing  
6/13/2014Robert J ReadyDirectorSell2,700$20.03$54,081.00View SEC Filing  
12/5/2013Vecheslav ElaginEVPSell4,141$23.74$98,307.34View SEC Filing  
11/22/2013Susan RolihEVPSell9,086$24.18$219,699.48View SEC Filing  
11/21/2013Richard EberlyEVPSell4,926$24.50$120,687.00View SEC Filing  
11/19/2013Lawrence BaldiniVPSell4,926$24.26$119,504.76View SEC Filing  
11/11/2013John KraeutlerCEOSell5,250$25.27$132,667.50View SEC Filing  
7/26/2013Lawrence BaldiniVPSell32,000$24.14$772,480.00View SEC Filing  
5/1/2013John A KraeutlerCEOBuy5,000$19.63$98,150.00View SEC Filing  
12/3/2012Lawrence BaldiniVPSell32,500$20.00$650,000.00View SEC Filing  
11/13/2012Robert J ReadyDirectorSell1,800$19.46$35,028.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Meridian Bioscience (NASDAQ VIVO) News Headlines

Source:
DateHeadline
Meridian Bioscience Inc. (VIVO) Receives Average Recommendation of "Hold" from BrokeragesMeridian Bioscience Inc. (VIVO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 14 at 3:54 AM
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Meridian Bioscience, Inc. – VIVOEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Meridian Bioscience, Inc. – VIVO
finance.yahoo.com - December 13 at 10:56 AM
The Klein Law Firm Notifies Investors of Commencement of a Class Action on Behalf of Meridian Bioscience, Inc. Shareholders and a Lead Plaintiff Deadline of January 16, 2018The Klein Law Firm Notifies Investors of Commencement of a Class Action on Behalf of Meridian Bioscience, Inc. Shareholders and a Lead Plaintiff Deadline of January 16, 2018
finance.yahoo.com - December 13 at 10:56 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVOSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVO
www.prnewswire.com - December 12 at 4:30 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) & Lead Plaintiff Deadline: January 16, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) & Lead Plaintiff Deadline: January 16, 2018
finance.yahoo.com - December 11 at 11:17 AM
Meridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q4, 2017 By the Numbers : December 11, 2017Meridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q4, 2017 By the Numbers : December 11, 2017
finance.yahoo.com - December 11 at 11:17 AM
VIVO EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Meridian Bioscience, Inc. and a Lead Plaintiff Deadline of ...VIVO EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Meridian Bioscience, Inc. and a Lead Plaintiff Deadline of ...
www.businesswire.com - December 8 at 4:20 PM
VIVO INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Meridian Bioscience, Inc. InvestorsVIVO INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Meridian Bioscience, Inc. Investors
finance.yahoo.com - December 8 at 4:20 PM
VIVO EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Meridian Bioscience, Inc. and a Lead Plaintiff Deadline of January 16, 2018VIVO EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Meridian Bioscience, Inc. and a Lead Plaintiff Deadline of January 16, 2018
finance.yahoo.com - December 8 at 4:20 PM
$49.74 Million in Sales Expected for Meridian Bioscience Inc. (VIVO) This Quarter$49.74 Million in Sales Expected for Meridian Bioscience Inc. (VIVO) This Quarter
www.americanbankingnews.com - December 7 at 2:58 AM
ETFs with exposure to Meridian Bioscience, Inc. : December 5, 2017ETFs with exposure to Meridian Bioscience, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 4:19 PM
VIVO INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Meridian Bioscience, Inc. and a Lead Plaintiff Deadline of January 16, 2018VIVO INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Meridian Bioscience, Inc. and a Lead Plaintiff Deadline of January 16, 2018
finance.yahoo.com - December 5 at 12:18 PM
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Meridian Bioscience, Inc. (NASDAQ: VIVO) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action LawsuitINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Meridian Bioscience, Inc. (NASDAQ: VIVO) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - December 4 at 4:22 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) and Lead Plaintiff Deadline: January 16, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) and Lead Plaintiff Deadline: January 16, 2018
finance.yahoo.com - December 4 at 4:22 PM
Meridian Bioscience, Inc. :VIVO-US: Earnings Analysis: 2017 By the Numbers : December 1, 2017Meridian Bioscience, Inc. :VIVO-US: Earnings Analysis: 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 5:51 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Meridian Bioscience, Inc. and Set a Lead Plaintiff Deadline of January 16, 2018 -- VIVOSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Meridian Bioscience, Inc. and Set a Lead Plaintiff Deadline of January 16, 2018 -- VIVO
finance.yahoo.com - December 1 at 5:51 PM
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Meridian Bioscience, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action LawsuitSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Meridian Bioscience, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - December 1 at 5:51 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Meridian Bioscience, Inc. and Set a Lead Plaintiff Deadline of January 16, 2018 -- VIVOSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Meridian Bioscience, Inc. and Set a Lead Plaintiff Deadline of January 16, 2018 -- VIVO
feeds.benzinga.com - December 1 at 3:53 AM
Meridian Bioscience Inc (VIVO) Files 10-K for the Fiscal Year Ended on September 30, 2017Meridian Bioscience Inc (VIVO) Files 10-K for the Fiscal Year Ended on September 30, 2017
finance.yahoo.com - November 29 at 10:42 AM
Intersect ENT (XENT) vs. Meridian Bioscience (VIVO) Financial ComparisonIntersect ENT (XENT) vs. Meridian Bioscience (VIVO) Financial Comparison
www.americanbankingnews.com - November 28 at 11:52 PM
VIVO LOSS NOTICE: Rosen Law Firm Reminds Meridian Bioscience, Inc. Investors of Important Deadline in Class Action– VIVOVIVO LOSS NOTICE: Rosen Law Firm Reminds Meridian Bioscience, Inc. Investors of Important Deadline in Class Action– VIVO
finance.yahoo.com - November 28 at 4:18 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) and Lead Plaintiff Deadline: January 16, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) and Lead Plaintiff Deadline: January 16, 2018
finance.yahoo.com - November 28 at 11:39 AM
Cohen Milstein Sellers & Toll PLLC Announces Investigation of Meridian Bioscience, Inc.Cohen Milstein Sellers & Toll PLLC Announces Investigation of Meridian Bioscience, Inc.
finance.yahoo.com - November 23 at 6:14 PM
VIVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Meridian ...VIVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Meridian ...
www.businesswire.com - November 21 at 12:27 AM
VIVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Meridian Bioscience, Inc.VIVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Meridian Bioscience, Inc.
finance.yahoo.com - November 20 at 12:01 PM
Meridian Bioscience, Inc. (VIVO) Given Consensus Recommendation of "Hold" by AnalystsMeridian Bioscience, Inc. (VIVO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 19 at 3:44 AM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) and Lead Plaintiff Deadline: January 16, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) and Lead Plaintiff Deadline: January 16, 2018
finance.yahoo.com - November 18 at 10:04 AM
Robbins Arroyo LLP: Meridian Bioscience, Inc. (VIVO) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: Meridian Bioscience, Inc. (VIVO) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - November 18 at 10:04 AM
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Meridian Bioscience, Inc. (NASDAQ: VIVO) To Contact Brower Piven Before The Lead Plaintiff DeadlineSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Meridian Bioscience, Inc. (NASDAQ: VIVO) To Contact Brower Piven Before The Lead Plaintiff Deadline
finance.yahoo.com - November 18 at 10:04 AM
$0.14 EPS Expected for Meridian Bioscience, Inc. (VIVO) This Quarter$0.14 EPS Expected for Meridian Bioscience, Inc. (VIVO) This Quarter
www.americanbankingnews.com - November 18 at 5:12 AM
Meridian Bioscience Inc. (VIVO) Upgraded to Hold by Zacks Investment ResearchMeridian Bioscience Inc. (VIVO) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - November 17 at 4:42 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Meridian Bioscience, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2018 – VIVOSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Meridian Bioscience, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2018 – VIVO
finance.yahoo.com - November 16 at 5:55 AM
Critical Comparison: ICU Medical (ICUI) & Meridian Bioscience (VIVO)Critical Comparison: ICU Medical (ICUI) & Meridian Bioscience (VIVO)
www.americanbankingnews.com - November 15 at 1:24 AM
Only 3 Days Left To Cash In On Meridian Bioscience Inc (VIVO) Dividend, Is It Worth Buying?Only 3 Days Left To Cash In On Meridian Bioscience Inc (VIVO) Dividend, Is It Worth Buying?
finance.yahoo.com - November 13 at 11:14 AM
Meridian Bioscience Inc. to Post FY2018 Earnings of $0.67 Per Share, William Blair Forecasts (VIVO)Meridian Bioscience Inc. to Post FY2018 Earnings of $0.67 Per Share, William Blair Forecasts (VIVO)
www.americanbankingnews.com - November 13 at 7:54 AM
Short Interest Falls 13% For VIVOShort Interest Falls 13% For VIVO
www.thestreet.com - November 12 at 1:11 PM
Meridian Bioscience Inc. (VIVO) Plans $0.13 Quarterly DividendMeridian Bioscience Inc. (VIVO) Plans $0.13 Quarterly Dividend
www.americanbankingnews.com - November 12 at 9:02 AM
Meridian Bioscience Inc. (VIVO) Issues  Earnings Results, Beats Expectations By $0.01 EPSMeridian Bioscience Inc. (VIVO) Issues Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 9 at 4:52 PM
Meridian Bioscience Q4 Adj. Profit Matches View, Revenues Beat EstimatesMeridian Bioscience Q4 Adj. Profit Matches View, Revenues Beat Estimates
www.rttnews.com - November 9 at 9:32 AM
Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2018 Cash Dividend Rate, and Reaffirms Fiscal 2018 GuidanceMeridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2018 Cash Dividend Rate, and Reaffirms Fiscal 2018 Guidance
finance.yahoo.com - November 9 at 9:32 AM
Meridian Bioscience meets 4Q profit forecastsMeridian Bioscience meets 4Q profit forecasts
finance.yahoo.com - November 9 at 9:32 AM
Meridian Bioscience Inc. (VIVO) Updates FY18 Earnings GuidanceMeridian Bioscience Inc. (VIVO) Updates FY18 Earnings Guidance
www.americanbankingnews.com - November 9 at 9:26 AM
VIVO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Meridian Bioscience, Inc.VIVO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Meridian Bioscience, Inc.
finance.yahoo.com - November 7 at 6:06 PM
Meridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : November 6, 2017Meridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : November 6, 2017
finance.yahoo.com - November 7 at 1:06 PM
Robbins Arroyo LLP Is Investigating the Officers and Directors of Meridian Bioscience, Inc. (VIVO) on Behalf of ShareholdersRobbins Arroyo LLP Is Investigating the Officers and Directors of Meridian Bioscience, Inc. (VIVO) on Behalf of Shareholders
finance.yahoo.com - November 7 at 1:06 PM
Meridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : VIVO-US : November 3, 2017Meridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : VIVO-US : November 3, 2017
finance.yahoo.com - November 3 at 9:59 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Meridian Bioscience, Inc.INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Meridian Bioscience, Inc.
finance.yahoo.com - November 1 at 10:26 AM
Meridian Bioscience Inc. (VIVO) Set to Announce Earnings on WednesdayMeridian Bioscience Inc. (VIVO) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - November 1 at 8:12 AM
ACT NOW: Monteverde & Associates PC Announces an Investigation of Meridian Bioscience, Inc. - VIVOACT NOW: Monteverde & Associates PC Announces an Investigation of Meridian Bioscience, Inc. - VIVO
finance.yahoo.com - October 31 at 11:49 AM
Meridian Bioscience Inc. (VIVO) Given Average Rating of "Hold" by BrokeragesMeridian Bioscience Inc. (VIVO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 25 at 4:45 AM

SEC Filings

Meridian Bioscience (NASDAQ:VIVO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Meridian Bioscience (NASDAQ:VIVO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Meridian Bioscience (NASDAQ VIVO) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.